JUMPAIR: Decubitus Ulcers Diseases Diagnoses by means of Smart Anti-Decubitus System based on known Ulcers Activity Biomarkers

Informations projet

JUMPAIR

N° de convention de subvention: 709595

DOI

10.3030/709595

Projet clôturé

Date de signature de la CE 25 Novembre 2015

Date de début 1 Decembre 2015

Date de fin 31 Mai 2016

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

DOFREN SRL
Italy

Periodic Reporting for period 1 - JUMPAIR (JUMPAIR: Decubitus Ulcers Diseases Diagnoses by means of Smart Anti-Decubitus System based on known Ulcers Activity Biomarkers)

Période du rapport: 2015-12-01 au 2016-05-31

Résumé du contexte et des objectifs généraux du projet

The project JUMPAIR will benefit a large number of patients who has suffered decubitus ulcers (DeU) or they are running the risk to suffer it by remotely monitor ulcers biomarkers to improve early diagnoses, prevention and treatment, providing alerts when critical situations occurs.
JUMPAIR project meets the objectives of the topic PHC-12-2014 "Clinical Research for the validation of biomarkers and/or diagnostic medical devices": clinical validation of known DeU diagnoses biomarkers by means of an innovative medical device which a potential wider clinical deployment in very short time. First of all, there is no decubitus system in the market able to monitor the onset of decubitus ulcers and provide alerts in real time to the hospital for long-term diseases, including the implementation of intelligent algorithms and an innovative integrated measurement system embedded in textiles. Secondly, the prototype will be enhanced and validated by means of clinical trials in real conditions in the Hospitals setting of our European collaborators network.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The objectives reached during the Feasibility Study of Phase 1, so the main results of Phase 1 could be listed as follows:
• Thanks to the support of several Hospitals in Europe, a network of clinicians specialized in prevention and treatment of DeU collaborated with DOFREN to design the protocols to validate clinically the product JUMPAIR as DeU early diagnoses medical device as well as to obtain EC and FDA certification for its commercialization. They will participate in clinical trials by supplying both patients and dedicated clinical staff members.
• An advanced analysis of the suitable design for the anti-decubitus system, the software and sensors has been performed and the best performance electronic components has been identified.
• Potential manufacturers with the capacity for mass manufacturing have been identified and preliminary partnerships has been started.
• A complete Business Plan has been drafted considering the new detailed Market and Industry Analysis.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The final anti-decubitus system JUMPAIR will contribute to decrease the healthcare expenditure preventing the onset of decubitus and avoiding unnecessary hospitalizations and therapeutic treatments. We believe that there is an unmet need in that field, and the final systems allows a preventive and therapeutic care of decubitus ulcers having a great impact for physicians and patients who deal with this critical decubitus ulcers disease.

jumpair.jpg